chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I started getting symptoms of sinus drainage. I then started getting fatigue, low grade fever, cough, runny nose, and more drainage. I took a COVID-19 test that was positive. I went to a clinic and had a PCR COVID-19 test that was positive. I was given antibody infusion. I feel like this help with my symptoms. I still have lingering symptoms of chest congestion, cough, and tiredness.
2 pediatric doses of Vaqta were mixed together and given. Patient should have received an Adult hep a
Chills; fatigue; body aches; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the parent.  A 19 year-old male patient received bnt162b2 (BNT162B2), administered in arm left, administration date 17Apr2021 11:00 (Batch/Lot number: unknown) at the age of 19 years as dose 2, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (dose number 1, Time: 11:15, vaccine location Right arm), administration date: 27Mar2021, for COVID-19 immunization. The following information was reported: CHILLS (non-serious) with onset 18Apr2021 13:00, outcome "recovering", described as "Chills"; FATIGUE (non-serious) with onset 18Apr2021 13:00, outcome "recovering", described as "fatigue"; PAIN (non-serious) with onset 18Apr2021 13:00, outcome "recovering", described as "body aches". Therapeutic measures were taken as a result of chills, fatigue, pain. Additional information: Patient had no other medications in two/four weeks. Patient had no COVID prior vaccination and is not COVID tested post vaccination. Patient also had no known allergies. Patient treatment was reported as Advil.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
detected NO GROWTH since 4/22 ultrasound; identical imagining in size; Miscarriage / pregnancy loss; This is a spontaneous report from a contactable consumer (patient's mother). This consumer reported information for both mother and fetus. This is the fetal report.  A fetus patient of an unspecified gender received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), transplacental on 02Apr2021 12:00 (batch/lot number: EL9263) as 1st dose, single, and transplacental on 23Apr2021 10:00 (batch/lot number: ER8735) as 2nd dose, single for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. The patient's mother experienced miscarriage / pregnancy loss on 28Apr2021 15:30. It was further reported that confirmed pregnancy on 22Apr2021 at OBGYN via blood test, urine test, and ultra sound. Pfizer 2nd dose COVID vaccine administered on 23Apr2021. Began miscarriage on 28Apr2021. On 28Apr2021, OBGYN medical professionals detected no growth since 22Apr2021 ultrasound. Identical imagining in size. The adverse event resulted in doctor or other healthcare professional office/clinic visit. The outcome of the events was unknown.; Sender's Comments: Linked Report(s) : US-PFIZER INC-2021494131 maternal case
A nurse reported that a 6 month old male received his 1st dose of Prevnar on 5/3/00. Within 2-3 days, post vax, he developed a high fever, wheezing and shallow breathing. He recovered.
Swelling with  hard red tissue around injection site with a large red halo from elbow to shoulder cuff, called the doctor, was put on voicemail. Awaiting call I got in on the 26 August. Was examined by nurse and she witnessed blistering around the initial injection site.  Was given Acyclovir 800 mg to take 5 times a day for possibly 10 days in case it was stubborn. Gradually healed by the 30th of August.
Hypoxia, sats in 80's, dyspnea right chest pain s/p right breast abscess
11/4/21 pt presented to hosp with c/o SOB and diarrhea; positive test for COVID; acute on chronic respiratory failure with hypoxia secondary to COPD exacerbation and COVID pneumonia; BiPAP; Tocilizumab, steroids, vitamin C and zinc; pt's condition worsened and per death certificate pt died in the hospital (12/11/21)
L hand numbness started 3-28-08.  In ER 3-30-08; vaccine given.
5 year old child had 1 episode of emesis s\p D2 of Pfizer CV19 vaccination as indicated in this report.  Spoke with patient's mother today, she stated patient did not any further episodes of emesis and is back to her baseline.
This spontaneous report as received from a certified medical assistant refers to a 67 years old male patient with hyperlipidemia, polyps, gastrooesophageal reflux disease (GERD), hypertrophy and drug hypersensitivity to CELEBREX and VIAGRA. The patient's medical history included Guillain Barre Syndrome in 1977 after administration of an unspecified swine flu vaccine (manufacturer unknown) and the patient was hospitalized. The patient was vaccinated intramuscularly with a 0.5 ml dose of PNEUMOVAX 23 (lot # not reported). No other co-suspects were reported. Concomitant medications included pravastatin sodium and NEXIUM. It was reported that on an unknown date the patient may have developed Guillain Barre Syndrome after administration of PNEUMOVAX 23. The reporter stated that the patient was hospitalized at an unspecified hospital for an unspecified period. At the time of the report the patient was seeing an unspecified neurologist for the treatment of Guillain Barre Syndrome. No treatment information was reported. The outcome of may have developed Guillain Barre Syndrome was reported as not recovered. The relatedness for the reported event was not provided for PNEUMOVAX 23. Additional information is not expected.
he felt a lot better/seems to get up easier, he gets out of bed a little easier with the bar, he is able to speak more loudly and clearly; like he just had more energy; This is a spontaneous report received from contactable reporter(s) (Pharmacist).  A 73 year-old male patient received bnt162b2 (BNT162B2), administered in arm right, administration date 19Mar2021 (Lot number: EN6208) at the age of 73 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "immunocompromised" (unspecified if ongoing); "multiple system atrophy" (unspecified if ongoing), notes: like Parkinson's plus; states there is no cure and no medications.; "Neuropathy" (unspecified if ongoing); "blood pressure drops down to 60/40" (unspecified if ongoing); "stem cell", start date: 2019 (unspecified if ongoing), notes: probably 2 years ago; "Parkinson's" (unspecified if ongoing); "chiropractic cervical work" (unspecified if ongoing). Concomitant medication(s) included: SINEMET taken for parkinson's disease, start date: May2014; GABAPENTIN taken for neuropathy peripheral; MIDODRINE taken for blood pressure decreased. Past drug history included: Symmetrel for multiple system atrophy, reaction(s): "did not work"; Azilect for multiple system atrophy, reaction(s): "did not work". Vaccination history included: Bnt162b2 (Lot number: EN6200 in right arm as dose 1, single), administration date: 26Feb2021, when the patient was 73 years old, for COVID-19 immunisation. The following information was reported: THERAPEUTIC RESPONSE UNEXPECTED (non-serious) with onset 20Mar2021, outcome "unknown", described as "he felt a lot better/seems to get up easier, he gets out of bed a little easier with the bar, he is able to speak more loudly and clearly"; ENERGY INCREASED (non-serious) with onset 20Mar2021, outcome "unknown", described as "like he just had more energy". Relevant laboratory tests and procedures are available in the appropriate section.  Additional information: Patient was a hospice patient. Because of the multiple system atrophy (MSA) the patient energy levels are very low, he has difficulty with balance and difficulty walking and was reported that nothing can be done for MSA. Patient had tried medications, amantadine (SYMMETREL), rasagiline (AZILECT) and Zydago (as reported) but they did not work and had been discarded. The patient did not receive any other vaccine within 4 weeks prior to COVID-19 vaccine. The second dose was administered between 10:30 to 10:45. The patient had no adverse reaction but experienced an unexpected reaction to the vaccine. Reporter stated in terms of causality, she would really have to say yes and it was remarkable the reaction the patient had after the Pfizer COVID Vaccine; stated the patient has an aid out there every day that exercises with him and the aid stated how much better the patient's circulation was and his strength on exercises has improved.  No follow-up attempts are possible. No further information is expected.
Patient reports extreme pain, discomfort, and limited range of motion in left arm/shoulder.  Patient was advised to see her doctor which she states she will do but has not yet.
some pain in chest/severe pain in my chest; This is a spontaneous report from a contactable consumer (patient). A 77-year-old male patient second dose of received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, Batch/Lot Number: EW0171) via an unspecified route of administration, administered in left arm on 04May2021 at 18:00 (at the age of 77-year-old) as dose 2, single for covid-19 immunisation at Pharmacy or Drug Store. Medical history reported as none. There were no concomitant/ other medications taken in 2 weeks. No other vaccine administered in four weeks. The patient previously received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, Batch/Lot Number: EWD1S3) via an unspecified route of administration, administered in left arm on 13Apr2021 18:00 (at the age of 77-year-old) as dose 1, single for covid-19 immunisation. On 25May2021 09:00, the patient experienced some pain in chest/severe pain in my chest. Patient reported prior to a trip during climbing stairs experienced some pain in chest. The again during a trip to airport while pushing the baggage cart experienced severe pain in his chest. Then he rested for 10 minutes the pain subsided then resurfaced again. He never ever had chest pain in his entire life or received any cardiovascular treatment ever. His blood pressure always has been normal. He was hoping it will go away on its own and waited until he made a cardiovascular specialist doctor appointment on 08Mar2021. He recommended and scheduled whole bunch of tests yet to be performed. He consider himself a very healthy person and has not been taking any medication in his entire life. The patient underwent lab tests and procedures which included blood pressure measurement resulting normal on an unspecified date. Patient didn't had covid prior vaccination and not been tested for covid post vaccination. No treatment was taken for adverse event. Chest pain resulted in doctor/ other healthcare professional office/clinic visit. Outcome of the event was not recovered at the time of reporting.  Follow-up attempts are completed. No further information is expected.
Dizzy, vomiting, hard to breathe, face turned yellow, diarrhea, exhaustion, the symptoms lasted less than 24 hours with a full recover immediately when symptoms disappeared. Patient has a history, and family history of allergies to measles vaccination and Tdap which is why the Td was given, had been given Td once before with no adverse effects, however, this time displayed same symptoms as previous allergic reactions.
Red, raised rash on right thigh. TYLENOL. Cetirizine, BENADRYL.
Swelling, tingling of lips; chest pressure; bilateral tingling of hands.  No SOB, No palpitations, No chest pain, No s/sx of angioedema.  A rapid response. Patient observed x 1 hour. No worsening of symptoms. Patient went home.
Initial unsolicited report received from a physician on 04 May 2015. A male patient (age not reported), whose medical history and concomitant medications were not reported, had received a dose of TYPHIM VI (batch number, expiry date, dose, dose number, route and site of administration were not reported) on unspecified date of April 2015. On April 2015, i.e. after vaccination on an unspecified date, patient had metabolic panel done within a few days with elevated liver enzymes and AST was 750. Illness at the time of vaccination and pre-existing physician diagnosed allergies, birth defects, medical conditions were reported as not applicable. Laboratory investigations and corrective treatment were not reported. At the time of this report, the outcome of event was unknown. Documents held by sender: none.
Administered ZOSTAVAX vaccine. Within 5 minutes patient experienced anaphylactic reaction-said her throat was closing and could not breath-administered 1 dose of epinephrine-complete recovery.
This patient was fully vaccinated/booster with Pfizer, life long non smoker presented to the ED 1/ 13/22 with sob and cough that worsened. He was also very weak but no reports of any fall s. Checked for COVID and saw his PCP on 1/12/22  prior to ED visit. He was placed on CPAP in the field/EMS and did not do well. Seen in ER for SOB and pulse OX 88%-90% unable to get satisfactory O2 and patient required intubation in ER. Repeat chest x-ray showed persisting infiltrates.  Patient was admitted to ICU.  treated with dexamethasone in case patient is suffering from COVID related respiratory failure. Pt terminally extubated at 1920. Pt expired at 2030.
A report was received from a health care professional on 12/3/03 concerning a female vaccinee in her 40's who developed a vaginal ulcer with symptoms to burning on urination and urgency on 11/13/03 after receiving Fluvirin vaccine on 11/12/03. Within 24 hours of receiving Fluvirin on 11/12/03 the vaccinee developed a vaginal ulcer with symptoms of burning on urination and urgency. The vaccinee was seen by the OB/GYN and was prescribed a vaginal anti-fungal cream for 4 days. The vaccinees vaginal ulcer resolved following completion of the anti-fungal therapy, however, she still complains of burning on urination and a feeling of urgency. The vaccinee was restarted on the vaginal anti-fungal cream and continues this therapy. The vaccinee had a test for yeast yielding negative results. Update 1/24/04: A follow up report was received from a health care professional indicating that a urologist treated the vaccine. She was given multiple medications including anti-inflammatories and antibiotics. The urologist felt that the vaccinee had interstitial cystitis which had no relationship to the flu vaccine. At the time of the follow up report the ulcer had disappeared but the urinary symptoms were unresolved. Update 2/23/04: A follow up report was received from a health care professional indicating that the vaccinee has been diagnosed with interstitial cystitis and continues to have symptoms. No follow up pending, all information received.
Consumer received 2 dose series completion in Feb 2021. She did not receive booster. Tested positive for covid this morning 07Jan2022; Consumer received 2 dose series completion in Feb 2021. She did not receive booster. Tested positive for covid this morning 07Jan2022; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP) from a sales representative. The reporter is the patient.  A 39 year-old female patient received bnt162b2 (BNT162B2), administration date Feb2021 (Batch/Lot number: unknown) as dose 2, single and administration date Feb2021 (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 07Jan2022, outcome "unknown" and all described as "Consumer received 2 dose series completion in Feb 2021. She did not receive booster. Tested positive for covid this morning 07Jan2022". The patient underwent the following laboratory tests and procedures: body temperature: (07Jan2022) about 101; sars-cov-2 test: (07Jan2022) positive. Clinical information: Consumer received 2 dose series completion in Feb2021. She did not receive booster. Tested positive for covid this morning 07Jan2022. She said she was exposed to covid as her 17-year-old daughter was having fever symptoms on 02Jan2022 who has also tested positive. 17-year-old daughter received 2 dose series (May2021) but not booster. Both experienced fever at about 101 and fatigue from covid.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Patient called 11/13/13 reporting of signs/symptoms of red, swollen area that is warm to touch where vaccine was administered on 11/11/13. She did see doctor but no idea as to what the treatment was.
Injection site pain; Tiredness; Headache; Chills; Fever was 101.6; Injection site redness; Nausea; Not feeling well; Felt bad; Weakness; Soreness arm; This is a spontaneous report from a contactable consumer. This 76-year-old female consumer (patient) reported that she received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection), via an unspecified route of administration on 21Feb2021 at single dose for COVID-19 immunisation. Medical history included Pulmonary hypertension and high blood pressure from an unknown date and unknown if ongoing. Patient previously took first dose of vaccine for Covid-19 immunisation. Concomitant medication not reported. When probed for the concern, consumer stated, "I was just calling to pass on my experience with the second vaccine. I ended up having all of the side effects that you had listed. I have injection site pain and redness and it still is as up today and I had the injection on Tuesday (23Feb2021). I had tiredness, headache, chills, fever and my fever was 101.6, injection site redness, nausea and basically not feeling well and I also had some weakness and I think that was because, I mean I felt so bad I was pretty much in bed and today is my first day up since Tuesday." The patient underwent lab tests and procedures on unspecified date which included Body temperature: 101.6. The outcome of the events Injection site redness, Soreness arm was reported as not recovered and outcome for other events was recovering.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
His arm was puffy and swollen; This is a spontaneous report from a contactable consumer. A male patient of an unspecified age received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Lot Number: EL9267), via an unspecified route of administration on 16Feb2021 as single dose for COVID-19 immunisation. The patient's medical history and concomitant medications were not reported. The patient got a shot (vaccine) on 16Feb2021 in the morning. He woke up on morning of 17Feb2021 and his arm was puffy and swollen. The reporter wanted to know if this is one of the side effects as she did not see that on the sheet. The outcome of the event was unknown.
Patient had a rash on the side of her arm where she received the Pneumovax vaccine on 9/17/13. She wen to MD on 9/19/13 and was presented an oral steroid and topical cream.
This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a female patient of unknown age. Information regarding medical history, concurrent conditions and concomitant medications was not provided. In 2007, the patient was inoculated with ZOSTAVAX at the department of health/healthcare facility, as recommended for routine adult health maintenance and for the long-term prevention of shingles (dose, route, and lot # not provided). The vaccine did not prevent shingles as intended, and the patient subsequently contracted a persistent strain of herpes zoster. In 2016, the patient was treated by a physician for the onset of a vesicular rash accompanied by weakened immune symptoms, which was diagnosed as severe herpes zoster, or shingles. As a direct and proximate result of the ZOSTAVAX vaccine, and/or despite receiving ZOSTAVAX for long-term prevention of shingles, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, and pain and suffering, and other damages. The outcome of the events was unknown. Causality assessment was related. Additional information has been requested.
Left arm hurt, but red bumps appeared on middle back late the next day. (Thursday)  Started itching on the second day (Friday), red spots broke out more broadly, and spread across right back and around to under right breast.  Painful, burning,  and itching. Took pictures and sent them to Doctor.  She responded late on the second day and prescribed Valacyclovir (3 times a day) which we obtained and started taking Saturday morning.  Bumps were more raised that day, but have not spread more, although much of the middle and upper back have the same pain, itching and burning.  Had video meeting with Dr. early Monday.  She said it was Shingles.  We are continuing with Valacyclovir, Tylenol, and occasional baking soda and powder with corn starch, and spray Calamine solution.  Also taking Loratidine.
This spontaneous report has been received from a medical assistant and refers to a 5-year-old patient of unknown gender. There was no information about the patient's concurrent conditions, concomitant therapies or medical histories provided. On 13-APR-2017, the patient was vaccinated with improperly stored dose of PROQUAD lot # M041083, expiration date 04-APR-2018 (dose and route of administration were not reported). There was no adverse effect reported. Vaccine was reconstituted with properly stored sterile diluent. Administered dose of vaccine experienced the temperature excursion between 15 to 46 degrees Fahrenheit (F) (22.3 (F)) for 1 hour and 3 minutes. Digital data logger was involved. There were no previous excursions reported. No product quality complaint was involved. The reporter also stated that she had a printed report of the patients who received vaccines that had undergone the temperature excursion. The report included vaccine name, date given lot number and the name, gender and birth date of patient. This is one of several reports received from the same reporter. Additional information is not expected as all relevant correspondence has already been received. This report was previously submitted with the incorrect Worldwide unique case identification number US-009507513-1705USA005093', and this new follow-up submission is to provide the correct identification number US-009507513-1706USA003934'. US-009507513-1705USA005093' is an existing case, therefore this safety report is not being nullified, just updated to reflect correct Worldwide Unique identification number. Sender's Comments: US-009507513-1705USA005086: US-009507513-1705USA005094: US-009507513-1705USA005093: US-009507513-1706USA003935: US-009507513-1706USA003936: US-009507513-1706USA003937.
This spontaneous report received from a medical assistant referred to a patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant medications were not reported. On an unknown date, the patient was vaccinated with an improperly stored M-M-R II (lot and expiry date: not reported) (incorrect product storage). The vaccine was exposed to a temperature of 50F and a minimum temperature of 35F for an unknown time frame. No adverse effects were reported.  There was no prior temperature excursions.  This is one of the four reports received from the same reporter.  Additional information has been requested.